We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+18.11%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.92B
AUM Growth
+$563M
Cap. Flow
+$217M
Cap. Flow %
4.4%
Top 10 Hldgs %
40.18%
Holding
111
New
29
Increased
28
Reduced
20
Closed
14
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$126M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$95.6M
3
AXSM icon
Axsome Therapeutics
AXSM
+$76.9M
4
BIO icon
Bio-Rad Laboratories Class A
BIO
+$72.2M
5
PRTA icon
Prothena Corp
PRTA
+$62.2M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$186M
2
JNJ icon
Johnson & Johnson
JNJ
+$160M
3
MCK icon
McKesson
MCK
+$127M
4
UNH icon
UnitedHealth
UNH
+$124M
5
ABBV icon
AbbVie
ABBV
+$116M

Sector Composition

Rank Sector Weight
1 Healthcare 90.59%
2 Miscellaneous 8.92%
3 Financials 0.49%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
LLY icon
1
Eli Lilly
LLY
$1.12T
$326M 6.62%
1,007,000
+397,000
+65% +$126M
2022 Q2
1 quarter
XNTK icon
2
CALL
State Street SPDR NYSE Technology ETF
XNTK
$1.99B
$321M 6.53%
+4,052,000
New +$441M
2022 Q3
0 quarters
UTHR icon
3
United Therapeutics
UTHR
$23.2B
$203M 4.13%
970,200
+244,600
+34% +$54.7M
2021 Q2
5 quarters
NBIX icon
4
Neurocrine Biosciences
NBIX
$13.9B
$197M 4.01%
1,855,700
+388,100
+26% +$39.4M
2020 Q4
7 quarters
ARVN icon
5
Arvinas
ARVN
$468M
$193M 3.93%
4,343,500
+987,877
+29% +$48M
2020 Q2
9 quarters
ARGX icon
6
argenx
ARGX
$53.2B
$174M 3.53%
491,800
-80,700
-14% -$29.9M
2022 Q1
2 quarters
BIIB icon
7
Biogen
BIIB
$34.8B
$160M 3.26%
600,000
+159,434
+36% +$33.9M
2022 Q1
2 quarters
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$129B
$148M 3.02%
512,800
-280,200
-35% -$80.6M
2020 Q4
7 quarters
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.22B
$134M 2.73%
5,586,900
+136,900
+3% +$3.07M
2020 Q2
9 quarters
PRTA icon
10
Prothena Corp
PRTA
$436M
$119M 2.42%
+1,967,000
New +$62.2M
2022 Q3
0 quarters
XBI icon
11
State Street SPDR S&P Biotech ETF
XBI
$9.9B
$117M 2.39%
1,480,000
-395,000
-21% -$33.3M
2022 Q1
2 quarters
ACHC icon
12
Acadia Healthcare
ACHC
$2.89B
$109M 2.21%
1,389,200
+354,200
+34% +$28.3M
2022 Q2
1 quarter
AKRO icon
13
DELISTED
Akero Therapeutics
AKRO
$106M 2.16%
+3,122,000
New +$47.8M
2022 Q3
0 quarters
SRPT icon
14
Sarepta Therapeutics
SRPT
$1.88B
$105M 2.13%
+948,200
New +$95.6M
2022 Q3
0 quarters
HUM icon
15
Humana
HUM
$51.9B
$103M 2.09%
212,000
-200,300
-49% -$97.4M
2022 Q1
2 quarters
BSX icon
16
Boston Scientific
BSX
$64B
$98.3M 2%
2,538,600
+13,600
+0.5% +$546K
2022 Q1
2 quarters
IMCR icon
17
Immunocore
IMCR
$1.52B
$97.6M 1.98%
2,079,100
+729,100
+54% +$34.7M
2021 Q1
6 quarters
KRTX icon
18
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$97.1M 1.97%
431,800
+227,230
+111% +$46M
2022 Q2
1 quarter
ELV icon
19
Elevance Health
ELV
$92.9B
$94.3M 1.92%
207,600
-233,400
-53% -$112M
2021 Q4
3 quarters
HZNP
20
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$91.7M 1.87%
1,482,200
-374,700
-20% -$26.2M
2019 Q4
11 quarters
ZNTL icon
21
Zentalis Pharmaceuticals
ZNTL
$212M
$91.5M 1.86%
4,223,100
+637,219
+18% +$17.4M
2020 Q2
9 quarters
AVTR icon
22
Avantor
AVTR
$10.9B
$88.6M 1.8%
4,522,600
-2,130,100
-32% -$57.1M
2020 Q2
9 quarters
RARE icon
23
Ultragenyx Pharmaceutical
RARE
$1.5B
$85M 1.73%
2,051,600
+572,100
+39% +$29.4M
2021 Q3
4 quarters
NTRA icon
24
Natera
NTRA
$58.3B
$76M 1.55%
1,735,000
+365,900
+27% +$17.4M
2020 Q3
8 quarters
AXSM icon
25
Axsome Therapeutics
AXSM
$8.47B
$68.7M 1.4%
+1,538,600
New +$76.9M
2022 Q3
0 quarters
1
2 3 4 5

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Avidity Partners Management's Q3 2022 Portfolio in Review

As of Q3 2022, Avidity Partners Management held 111 positions worth $4.92B, up 13% from $4.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Avidity Partners Management deployed $217M of net new capital in Q3 2022, opening 29 new positions and adding to 28 existing holdings. Its largest new stake was Sarepta Therapeutics: 948,200 shares worth $105M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was AstraZeneca, an estimated $186M trimmed.

  • Avidity Partners Management's largest Q3 2022 buy was Sarepta Therapeutics: 948,200 shares worth $105M.
  • Avidity Partners Management added most to Eli Lilly in Q3 2022, an estimated $126M increase.
  • Avidity Partners Management's biggest Q3 2022 reduction was AstraZeneca, cutting an estimated $186M.
  • Avidity Partners Management fully exited Johnson & Johnson in Q3 2022, selling an estimated $160M.
  • Avidity Partners Management's ten largest holdings make up 40% of its $4.92B portfolio in Q3 2022.
  • Avidity Partners Management opened 29 new positions and closed 14 in Q3 2022.
  • Avidity Partners Management's portfolio value rose 13% quarter-over-quarter to $4.92B.

Based on Avidity Partners Management's 13F filing for Q3 2022, filed 14 Nov 2022.